Nathaniel Brown, MD

Hepatitis B Foundation Board of Directors and Scientific Advisory Board
Adjunct Professor of Experimental Therapeutics, Baruch S. Blumberg Institute
Retired biotech/pharma clinical executive (Focus on HBV and HCV)

  • Education & Training
    • Yale U., B.S., Molecular Biophysics & Biochemistry
    • Georgetown U. School of Medicine (M.D. 1976)
    • Clinical training & virology research training at Cornell & Yale
  • Professional Career – Full-Time Academic Medicine (7 yrs)
    • Assistant Professor, U.C.L.A. School of Medicine
    • Associate Professor, Cornell Medical College
    • Academic career with continuous NIH R01 research grant funding
  • Fulltime Biotech/Pharma Positions (27 yrs)
    • Hepatitis Section Head, GlaxoWellcome/GlaxoSmithKline
    • Chief Medical Officer for (in order):  Idenix Pharmaceuticals, Presidio Pharmaceuticals, Novira Therapeutics
  • Research Interests and Career Focus
    • Viral pathogenesis, especially human oncogenic viruses
    • Clinical development of antiviral medicines for HBV, HCV, and HIV infections
      • Led the global clinical trial programs for 1st and 3rd HBV nucleoside antivirals
      • Led early clinical proof-of-concept trials for 1st HBV core inhibitor